Background-The implantable cardioverter-defibrillator (ICD) is the most effective treatment for preventing arrhythmic deaths in patients with heart failure, but periprocedural complications, including in-hospital mortality or cardiac arrest, may occur, and little is known about risk factors. We asked whether elevated B-type natriuretic peptide (BNP) level is associated with increased risk of in-hospital mortality or cardiac arrest in patients undergoing ICD implantation. Methods and Results-From the National Cardiovascular Data Registry ICD Registry, we identified 53 198 patients who received ICD implants and underwent preoperative BNP measurement from 2006 to 2008. The patients were categorized into 4 groups by BNP levels (Ͻ100, 100 to Ͻ300, 300 to Ͻ1000, and Ն1000 pg/mL). Complication rates were compared among groups, and odds ratios for in-hospital mortality or cardiac arrest were estimated by multiple hierarchical logistic regressions. There were 2952 complications reported, including 510 in-hospital deaths and 365 cardiac arrests. The rate of in-hospital mortality or cardiac arrest significantly increased with elevated BNP level (PϽ0.001). The adjusted odds ratios of in-hospital mortality or cardiac arrest were statistically significant in all 3 higher BNP groups [odds ratio (95% CI), 1.99 (1.17 to 3.39), 2.49 (1.50 to 4.13), and 4.25 (2.57 to 7.06) in the second, third, and fourth groups using Ͻ100 as reference]. Among subgroups, the association was more significant in men, patients with renal dysfunction, and patients undergoing biventricular ICD implantation.
ness of therapy. BNP is a peptide hormone released primarily from the ventricles in response to increases in ventricular pressure and myocardial stretch. 7 Recent studies show that BNP can independently predict mortality in acute and/or chronic coronary heart disease and chronic heart failure. 8 -10 Verma et al 11 found that a single preimplantation BNP concentration determination can predict further malignant ventricular arrhythmias in patients with cardiomyopathies undergoing ICD implantation. BNP has also been found to be the only independent predictor of sudden death in a large number of patients with chronic heart failure. 12 However, whether elevated BNP level is associated with increased risk of periprocedural complications in patients undergoing ICD implantation is unknown.
To address this question, we analyzed data from the National Cardiovascular Data Registry (NCDR) ICD Registry, 13 a national registry that contains demographic characteristics, clinical information, and in-hospital outcomes for patients undergoing ICD implantation. We investigated the association of preoperative level of BNP with periprocedural complications, particularly in-hospital mortality or cardiac arrest, in patients undergoing ICD implantation, and further evaluated this association in subgroups, including sex, renal function, and ICD type.
WHAT IS KNOWN
• Elevated BNP is associated with increased perioperative mortality. • ICD implantation is usually well tolerated but occasionally results in death or postimplant cardiac arrest.
WHAT THE STUDY ADDS
• Markedly elevated BNP before ICD implant is associated with a significantly higher risk of death or cardiac arrest. • Preoperative BNP Ն1000 pg/mL and biventricular ICD implantation is associated with a 2.16% mortality in real world practice. • Preimplantation risk assessment should include measurement of BNP.
Methods

Data Source
The data were obtained from the NCDR ICD Registry, which was developed by American College of Cardiology and Heart Rhythm Society in response to the Centers for Medicare and Medicaid Services to finalize the national coverage determination for ICD implantation. Although the initial goal of the Centers for Medicare and Medicaid Services for the ICD Registry was to determine whether primary prevention ICD implantation procedures are appropriate for Medicare beneficiaries, the registry captured about 88% of implants being performed in hospitals regardless of device indication or patient age in their reporting periods. 14 The registry collected 130 data elements, including detailed information about demographics, clinical and procedural information, and adverse events during or after the procedure until discharge. The data were standardized and the quality was examined with NCDR Data Quality Reporting process. 15
Patient Population
Between January 1, 2006, and December 31, 2008, the ICD Registry collected data on a total of 273 713 patients with ICD implants from 1300 hospitals. From these data, the analytic cohort of 53 198 subjects for the current study was constructed, including subjects who had (1) either primary or secondary prevention indication for ICD implantation and (2) serum biomarker (BNP) concentration determined from blood before implantation.
Data Collection
The primary end point was defined as the occurrence of any periprocedural complication after ICD implantation. Complications that occur during or after the procedure until the time of hospital discharge were reported by implanting centers using standard definitions. . For all variables except left ventricular ejection fraction (1.32%), the rate of missing values was Ͻ1%. Accordingly, for categorical variables, missing data were imputed as the most common value among those with the data present. For continuous variables, the missing values were imputed as the median among those with the data present.
Statistical Analysis
For the crude differences in patient demographic characteristics, clinical factors, and periprocedural complications across different levels of BNP, we reported meanϮSD values for continuous variables and number and percentage (%) for categorical variables; the 2 test in frequency table analyses for categorical variables and the F test in ANOVA analyses for continuous variables for comparison across the different BNP levels were used and the corresponding probability values were reported. We constructed several hierarchical logistic regression models 16 to assess the independent association between BNP levels and (1) in-hospital mortality and (2) cardiac arrest. The occurrence of either adverse event was used as dependent variable, and selected patient characteristics (demographics and clinical factors) as well as the BNP levels were used as independent variables. In the model, we characterized BNP levels using 3 dummy variables indicating the BNP levels of "100 to Ͻ300 pg/mL," "300 to Ͻ1000 pg/mL," and "Ն1000 pg/mL" (with BNP Ͻ100 pg/mL as reference group) and used patient demographic variables and clinical factors for risk adjustment. All the variables were included sequentially in the models for adjustment and odds ratios of BNP levels on in-hospital mortality or cardiac arrest were reported. The association of BNP with in-hospital mortality or cardiac arrest was also assessed in prespecified subgroups, including sex, renal function, and ICD type. Renal dysfunction was defined by BUN Ն30 mg/dL or creatinine Ն1.5 mg/dL or a patient with renal failuredialysis. We also examined the impact of BNP on in-hospital mortality or cardiac arrest in subgroups of ICD indication (primary prevention versus secondary prevention) and hospitalization reason (admitted for procedure, hospitalized cardiac, and hospitalized noncardiac). Multivariable hierarchical logistic regression models were constructed by using the same approach as the full-risk models, stratified by prespecified subgroups. All analyses were performed at Yale University using SAS statistical software version 9. The baseline characteristics, the diagnostic status, and the procedural type stratified by specified BNP categories are shown in Table 1 . Patients with higher levels of BNP were older, more likely to have been hospitalized for cardiac reasons, more likely to have a history of CHF, current NYHA class III or IV symptoms, and renal failure-dialysis. The ejection fraction assessed before the procedure was inversely associated with BNP level. Patients with higher levels of BNP were also more likely to have increased QRS duration, increased rate of atrioventricular conduction block, and abnormal intraventricular conduction. The serum creatinine level or BUN level was significantly associated with increased BNP level. All other demographic and clinical characteristics were statistically different across BNP levels, but most of these differences might not be clinically relevant or biologically plausible.
Relation of BNP Levels and Periprocedural Adverse Events After ICD Implant
There were totally 2952 complications reported, including 510 in-hospital deaths and 365 cardiac arrests of 53 198 subjects who received ICD implants and had preoperative BNP measurement. The crude rates of periprocedural adverse events after ICD implant stratified by 4 specified BNP categories are shown in Table 2 . The rate of any events, major events, and minor events was significantly increased in the second, third, and fourth BNP groups compared with the first BNP group. When adverse events were considered individually, the incidence of in-hospital mortality, cardiac arrest, coronary vein dissection, hematoma, and hemothorax were significantly increased at higher BNP groups. The coronary artery bypass surgery and percutaneous coronary intervention were also significantly increased at higher BNP groups, but transient ischemic attack, cerebrovascular accident/stroke, and myocardial infarction were not. Among individual events, in-hospital mortality or cardiac arrest was strongly associated with increased BNP (PϽ0.001). The rate of in-hospital mortality or cardiac arrest in the highest BNP group was more than 10-fold than that in the lowest BNP group and appeared to have a near-linear relationship with increasing in BNP level (Figure 1) .
The unadjusted and adjusted odds ratios (ORs) with 95% confidence interval (CIs) for in-hospital mortality or cardiac arrest with BNP level as a categorical variable are shown in Table 3 . The unadjusted odds ratios of in-hospital mortality or cardiac arrest were significantly increased in the second, third, and fourth BNP groups compared with the first BNP group. In a hierarchical logistical regression model, after adjusting for multiple clinical variables, BNP level was still a 
Relation of BNP Levels and In-Hospital Mortality or Cardiac Arrest in Subgroup Populations
We further assessed the relationship of BNP and in-hospital mortality or cardiac arrest in subgroups of sex, renal function, and ICD type. The incidence of in-hospital mortality or cardiac arrest was substantially higher in males, patients with renal dysfunction, and patients undergoing CRT-D implantation compared with their counterparts under most BNP groups (Figure 2) . The adjusted OR with 95% confidence interval for in-hospital mortality or cardiac arrest stratified by BNP categories in 3 subgroups are shown in Figure 3 . With BNP Ͻ100 pg/mL as reference group, the adjusted OR was statistically significant in males, patients with renal dysfunction, and patients undergoing CRT-D implant at all 3 elevated BNP groups (marginally significant for patients with renal dysfunction at BNP level 100 to Ͻ300 pg/mL). In females, patients without renal dysfunction, and patients undergoing non-CRT-D implant, the ORs were larger than 1 but not statistically significant except in the highest BNP group (Ն1000 pg/mL) and in patients without renal dysfunction with BNP level 300 to Ͻ1000 pg/mL). We also examined the impact of BNP on in-hospital mortality or cardiac arrest in subgroups of ICD indication (primary prevention versus secondary prevention) and hospitalization reason (admitted for procedure, hospitalizedcardiac, and hospitalized noncardiac). The incidence of inhospital mortality or cardiac arrest was substantially higher in secondary prevention compared with primary prevention. When grouped by hospitalization reason, the incidence of in-hospital mortality or cardiac arrest was highest in hospitalized cardiac, followed by hospitalized noncardiac and then admitted for procedure ( Figure 4 ). With BNP Ͻ100 pg/mL as reference group, the adjusted OR for in-hospital mortality or cardiac arrest by BNP level were statistically significant in both primary prevention and secondary prevention at almost all 3 higher BNP groups (except at primary prevention with BNP 100 to Ͻ300 pg/mL, Pϭ0.14); the OR is slightly larger in the secondary prevention compared with primary prevention. In the subgroup of hospitalization reason, the adjusted OR was large and statistically significant in patients admitted for procedure at all 3 elevated BNP groups; however, in hospitalized cardiac and hospitalized noncardiac, the adjusted ORs were larger than 1 but not statistically significant except in the highest BNP group (Ն1000 pg/mL) ( Figure 5 ). These differences of BNP prediction for in-hospital mortality or cardiac arrest in subgroup populations will be discussed below and merits further investigation. 
Discussion
Our study demonstrates that elevated BNP measured preoperatively is strongly associated with an increased risk of in-hospital mortality or cardiac arrest in patients undergoing ICD implantation, particularly in males, patients with renal dysfunction, and patients undergoing CRT-D implantation. The present study expands the knowledge regarding the risk factors for serious periprocedural complications associated with ICD implantation.
Periprocedural in-hospital death and cardiac arrest represent the worst possible outcomes associated with ICD implantation. Peterson et al 17 reported that of 161 470 patients who underwent first-time ICD implantation between January 2006 and December 2007, 678 patients died in-hospital during or after the procedure, whereas 555 patients had a cardiac arrest. Previous studies demonstrated that an increased BNP could predict long-term mortality in acute and/or chronic coronary heart disease and heart failure. 8 -10,12 To our knowledge, this study is the first one to report that elevated preoperative BNP is a predictor of in-hospital death or cardiac arrest in patients undergoing ICD implantation. This study raises an important question of balancing acute risk and long-term benefit of ICD implantation in patients with high BNP. Although the demographic findings showed that elevated BNP values were associated with other risk factors (including age, sex, heart failure class, ejection fraction, QRS duration, atrioventricular/intraventricular conduction block, preexisting heart disease, and renal dysfunction), the association between BNP and in-hospital mortality or cardiac arrest was still significant after controlling for all these comorbidities. This finding indicates that BNP is an important marker of periprocedural risk that is independent of conventional indicators of left ventricular dysfunction or symptomatology. Additionally, BNP measurement is noninvasive and inexpensive, and therefore it might be a practical tool for predicting risk in patients who are undergoing ICD implantation. One might argue that the patients who are at high risk for in-hospital events are also at high risk for outpatient events and the highest BNP level patients might be the ones who derive the most benefit from ICD implant. This information regarding the relationship between BNP and severe procedural complications contributes to our ability to counsel patients regarding their personal risk in undergoing this common procedure and points to potential opportunities for risk mitigation.
The impact of increased BNP appeared to be particularly significant in certain subgroups, for example, men, patients with renal dysfunction, and patients undergoing CRT-D implant. Redfield et al 18 reported that BNP and NT-pro-BNP are significantly higher in women than in men at any age. The present study also showed an increased mean and median BNP in female patients compared with male patients (mean/ median, 1061/634 pg/mL in women versus 955/557 pg/mL in men). These results suggest that the increase in baseline BNP level in women may account for the reduced predictive value of BNP in the lower BNP groups. In patients with renal dysfunction, the rate of in-hospital mortality or cardiac arrest and the OR for in-hospital mortality or cardiac arrest by BNP level were significantly larger than that in patients without renal dysfunction. Although some studies suggest that renal insufficiency could increase the level of BNP by reducing BNP clearance, 19 there might be some additional detrimental factors that increase the risk of in-hospital mortality or cardiac arrest in patients with renal dysfunction. Recently, Hreybe et al 20 reported that patients with renal failure and hemodialysis had approximately a 3-fold increase in total mortality after ICD implantation compared with patients without renal failure and hemodialysis. Patients undergoing CRT-D implant appeared to have a higher rate of in-hospital mortality or cardiac arrest at all BNP levels above 100 pg/mL, and the OR for in-hospital mortality or cardiac arrest by BNP level was substantially larger than the OR in patients with non-CRT-D implant. Possible explanations for this increased morbidity associated with CRT-D include the added complexity of the procedure (which is associated with significantly longer procedure times) and the presence of more advanced heart failure in subjects requiring CRT-D than in those who received conventional ICDs. However, further analysis found that CRT-D procedure only was not a risk factor for in-hospital mortality or cardiac arrest in this patient population (Pϭ0.243). Subgroup analysis also showed that the BNP effects for in-hospital mortality or cardiac arrest were similar between primary prevention and secondary prevention. However, in patients hospitalized for procedure, the OR for in-hospital mortality or cardiac arrest by BNP level was substantially larger than the OR in hospitalizedcardiac and hospitalized noncardiac. Unfortunately, we found that whereas more than 55% of patients hospitalized cardiac had BNP measurement performed, only about 10% of patients hospitalized primarily for the ICD procedure underwent BNP measurement. This finding indicates that BNP has been not generally used as a risk factor for ICD implantation. Although it is impossible from this study to specify a "safe" BNP value with respect to avoiding periprocedural complications, it should be noted that when BNP level was Ͼ1000 pg/mL, the risk of in-hospital mortality or cardiac arrest was significantly higher in all subgroups of patients.
The explanation for the higher in-hospital mortality rate in patients with elevated levels of BNP is unknown and needs to be investigated. These periprocedural deaths might be due to anesthesia-related complications, procedure-related events, for example, induction of ventricular fibrillation, or any other severe adverse events after procedure. Because of limitations relating to registry, we were not able to extract the information on whether the complication was related to defibrillation threshold testing or some other procedural components from the current study. In a series of over 19 000 device implants with defibrillation testing, Birnie et al 21 noted 27 episodes of cardiac arrest with need for prolonged resuscitation. Because information on the timing and causes of death was not available in our study, it is impossible here to give a clear explanation of the relationship between increased in-hospital mortality and elevated BNP value in subjects undergoing ICD implantation. However, it is important that the role of elevated BNP in implant mortality be investigated prospectively because intensification of therapy has been shown to lower BNP. 22 One could speculate that a more aggressive attempt to reduce a patient's BNP level before implantation could significantly increase the safety of the procedure, but this putative strategy must be tested formally before adoption.
Our study has several important limitations relating to its "registry" nature. First, patients with BNP measurements that represented 20% of all registry patients had more severe heart failure and a higher rate of mortality and cardiac arrest than those not studied. Although we have adjusted for all the relevant clinical variables, including NYHA class and left ventricular ejection fraction, in our analytic model, the selection bias cannot be ruled out. Second, because there is no nonprocedure control group with high BNP, it is possible that the observed increased morbidity reflected their advanced heart failure and not the effects of the procedure. According to the TIME CHF study, 23 subjects with a median BNP of 4000 pg/mL had a 20% mortality at 18 months, equaling a monthly mortality of 1.11%, a rate far lower than observed in this study. It seems unlikely, then, that the increased mortality association observed in this study reflects the "natural history" for patients with increased BNP levels. Third, the time at which BNP was measured before ICD implantation is unknown. In some of the patients, BNP levels might have been drawn from admission rather than before the procedure. However, because the time between admission and procedure was short, it is unlikely that the BNP level would change significantly if a change occurred. Fourth, it should be noted that the multiple logistic models used here might not be able to adjust for all variables and the presence of residual confounding cannot be excluded and that the ORs obtained here were marginal estimates; in other words, they were averaged over hospitals and not population-averaged. Finally, the duration of follow-up was limited to the period of hospitalization. Thus, postdischarge complications could not be accounted for in our analysis.
In summary, preoperative BNP level was a significant and independent predictor for in-hospital mortality or cardiac arrest in patients undergoing ICD implantation. Strategies aimed at reducing preprocedural BNP or creating systems to better manage procedural risk in these high-risk patients to decrease complications associated with ICD implantation merit further investigation.
